Signaling pathways of apoE and its role of gene expression in glomerulus diseases

Journal of Receptors and Signal Transduction

Volumn 33, Issue 2, 2013, Pages 73-78

  Zhou, Tian Biao ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

ApoE; Glomerulus diseases; Signaling pathways

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN E; FIBROBLAST GROWTH FACTOR 1; PROTEIN PRECURSOR; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

GENE EXPRESSION; GLOMERULOPATHY; HUMAN; LIPOPROTEIN BLOOD LEVEL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

APOLIPOPROTEINS E; GENE EXPRESSION REGULATION; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIPIDS; SIGNAL TRANSDUCTION;

EID: 84875667569     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2013.765466     Document Type: Review

References (88)

1. Pande AH, Tripathy RK, Nankar SA. Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E. Biochim Biophys Acta 2009;1788:1366-76.
2. Luo CC, Li WH, Chan L. Structure and expression of dog apolipoprotein A-I, E: C-I mRNAs: implications for the evolution and functional constraints of apolipoprotein structure. J Lipid Res 1989;30:1735-46.
3. Zechner R, Moser R, Newman TC, et al. Apolipoprotein E gene expression in mouse 3T3-L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J Biol Chem 1991;266:10583-8.
4. Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res 2011;50:62-74.
5. Garcia MA, Vazquez J, Gimenez C, et al. Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. J Neurosci 1996;16:7550-6.
6. Lahiri DK. Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci 2004;23:225-33.
7. Zhou TB, Qin YH, Lei FY, et al. apoE expression in glomerulus and correlation with glomerulosclerosis induced by adriamycin in rats. Ren Fail 2011;33:348-54.
8. Zhou TB, Qin YH, Lei FY, et al. All-trans retinoic acid regulates the expression of apolipoprotein E in rats with glomerulosclerosis induced by Adriamycin. Exp Mol Pathol 2011;90:287-94.
9. Fan P, Liu H, Wang Y, et al. Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS. Reprod Biomed Online 2012;24:197-205.
10. Panin LE, Russkikh GS, Polyakov LM. Detection of apolipoprotein A-I, B, and E immunoreactivity in the nuclei of various rat tissue cells. Biochemistry (Mosc) 2000;65:1419-23.
11. Hsu CC, Kao WH, Coresh J, et al. Apolipoprotein E and progression of chronic kidney disease. JAMA 2005;293:2892-9.
12. Zhang H, Wu LM, Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflamm 2011;2011:949072.
13. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008;52:131-45.
14. Arora S, Husain M, Kumar D, et al. Human immunodeficiency virus downregulates podocyte apoE expression. Am J Physiol Renal Physiol 2009;297:653-61.
15. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
16. Yin C, Zhou S, Jiang L, Sun X. Mechanical injured neurons stimulate astrocytes to express apolipoprotein E through ERK pathway. Neurosci Lett 2012;515:77-81.
17. Zarow C, Victoroff J. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol 1998;149:79-86.
18. Boschert U, Merlo-Pich E, Higgins G, et al. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis 1999;6:508-14.
19. Yamagata K, Urakami K, Ikeda K, et al. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:57-62.
20. Grone HJ, Walli AK, Grone E, et al. Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. Kidney Int 1990;37:1449-59.
21. Li HF, Han CF, Wang YX, et al. Effect of apolipoprotein E gene polymorphism on serum lipid level before and after renal transplantation. Transplant Proc 2010;42:2513-7.
22. Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract 2010;114:260-7.
23. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. J Mol Med (Berl) 2005;83:329-42.
24. Sakashita K, Tanaka F, Zhang X, et al. Clinical significance of ApoE expression in human gastric cancer. Oncol Rep 2008;20:1313-9.
25. Su WP, Chen YT, Lai WW, et al. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer-J Iaslc 2011;71:28-33.
26. Ito Y, Takano T, Miyauchi A. Apolipoprotein e expression in anaplastic thyroid carcinoma. Oncol Basel 2006;71:388-93.
27. Elliott DA, Kim WS, Jans DA, Garner B. Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neurosci Lett 2007;416:206-10.
28. Kattan OM, Kasravi FB, Elford EL, et al. Apolipoprotein E-mediated immune regulation in sepsis. J Immunol 2008;181: 1399-408.
29. Zhou TB. Signaling pathways of PAX2 and its role in renal interstitial fibrosis and glomerulosclerosis. J Recept Signal Transduct Res 2012;32:298-303.
30. Zhou TB, Qin YH. The signaling pathways of LMX1B and its role in glomerulosclerosis. J Recept Signal Transduct Res 2012; 32:285-9.
31. Zhou TB, Qin YH. The potential mechanism for the different expressions of gelatinases induced by all-trans retinoic acid in different cells. J Recept Signal Transduct Res 2012;32:129-33.
32. Guttman M, Prieto JH, Handel TM, et al. Structure of the minimal interface between ApoE and LRP. J Mol Biol 2010;398:306-19.
33. Lu Y, Tian QB, Endo S, Suzuki T. A role for LRP4 in neuronal cell viability is related to apoE-binding. Brain Res 2007;1177:19-28.
34. Hoe HS, Rebeck GW. Functional interactions of APP with the apoE receptor family. J Neurochem 2008;106:2263-71.
35. Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol 2008;28:1060-7.
36. Rossello XS, Igbavboa U, Weisman GA, et al. AP-2beta regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes. Brain Res 2012;1444:87-95.
37. Kim E, Yang Z, Liu NC, Chang C. Induction of apolipoprotein E expression by TR4 orphan nuclear receptor via 5' proximal promoter region. Biochem Biophys Res Commun 2005;328:85-90.
38. Kurano M, Iso-O N, Hara M, et al. LXR agonist increases apoE secretion from HepG2 spheroid, together with an increased production of VLDL and apoE-rich large HDL. Lipids Health Dis 2011;10:134.
39. Kockx M, Rye KA, Gaus K, et al. Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J Biol Chem 2004;279:25966-77.
40. Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol 2008;28:1060-7.
41. Galetto R, Albajar M, Polanco JI, et al. Identification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control region. Biochem J 2001;357:521-7.
42. Bencharif K, Hoareau L, Murumalla RK, et al. Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids Health Dis 2010;9:75.
43. Nishida T, Ito J, Nagayasu Y, Yokoyama S. FGF-1-induced reactions for biogenesis of apoE-HDL are mediated by src in rat astrocytes. J Biochem 2009;146:881-6.
44. Ito J, Nagayasu Y, Lu R, et al. Astrocytes produce and secrete FGF-1, which promotes the production of apoE-HDL in a manner of autocrine action. J Lipid Res 2005;46:679-86.
45. Lu R, Ito J, Iwamoto N, et al. FGF-1 induces expression of LXRalpha and production of 25-hydroxycholesterol to upregulate the apoE gene in rat astrocytes. J Lipid Res 2009;50:1156-64.
46. Singh NN, Ramji DP. Transforming growth factor-beta-induced expression of the apolipoprotein E gene requires c-Jun N-terminal kinase, p38 kinase, and casein kinase 2. Arterioscler Thromb Vasc Biol 2006;26:1323-9.
47. Pons S, Hagege A, Fornes P, et al. Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure. J Cardiovasc Pharmacol 2003;42:17-23.
48. Stegbauer J, Potthoff SA, Quack I, et al. Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE- deficient mice. Br J Pharmacol 2011;163:974-83.
49. Diaz JA, Ballard-Lipka NE, Farris DM, et al. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg 2012;55:815-22.
50. Vaziri ND, Kim HJ, Moradi H, et al. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Nephrol Dial Transplant 2010;25:3525-34.
51. Hishikawa K, Nakaki T, Fujita T. Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-defi-cient mice. Arterioscler Thromb Vasc Biol 2005;25:442-6.
52. Xu S, Jiang B, Maitland KA, et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 2006;55: 110-9.
53. Bugnicourt JM, Da SC, Bengrine A, et al. Chronic renal failure alters endothelial function in cerebral circulation in mice. Am J Physiol Heart Circ Physiol 2011;301:1143-52.
54. Martinez-Miguel P, Raoch V, Zaragoza C, et al. Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins. J Lipid Res 2009;50: 364-75.
55. Xu ZE, Chen Y, Huang A, et al. Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA triple knockout mice. Am J Physiol Renal Physiol 2011;301:713-22.
56. Southworth R, Kaneda M, Chen J, et al. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine 2009;5:359-67.
57. Knowles JW, Reddick RL, Jennette JC, et al. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000;105: 451-8.
58. Wu JH, Hagaman J, Kim S, et al. Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arterioscler Thromb Vasc Biol 2002;22:469-75.
59. Gervais M, Pons S, Nicoletti A, et al. Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:183-9.
60. Kawamura A, Baitsch D, Telgmann R, et al. Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2007;27:1610-7.
61. Sheng Z, Prorok M, Brown BE, Castellino FJ. N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Neuropharmacology 2008;55:204-14.
62. Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem 2005;93: 145-55.
63. Hoe HS, Pocivavsek A, Dai H, et al. Effects of apoE on neuronal signaling and APP processing in rodent brain. Brain Res 2006;1112:70-9.
64. Chen G, Paka L, Kako Y, et al. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 2001;276:49142-7.
65. Hone E, Martins IJ, Fonte J, Martins RN. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 2003;5:1-8.
66. Irizarry MC, Deng A, Lleo A, et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 2004;90:1132-43.
67. Takamoto K, Kawada M, Ikeda D, Yoshida M. Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C. Biochim Biophys Acta 2005;1722:247-53.
68. Janis MT, Metso J, Lankinen H, et al. Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 2005;331:333-40.
69. Shen L, Wang DQ, Tso P, et al. Apolipoprotein E reduces food intake via PI3K/Akt signaling pathway in the hypothalamus. Physiol Behav 2011;105:124-8.
70. Ling Y, Li X, Gu Q, Gao X. Circulating ApoE level is independently associated with urinary albumin excretion in type 2 diabetic patients. Intern Med 2011;50:2961-6.
71. Deighan CJ, Caslake MJ, McConnell M, et al. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1. Kidney Int 2000;58:1238-46.
72. Attman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-42.
73. Pasquariello A, Pasquariello G, Innocenti M, et al. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J Nephrol 2011;24:381-5.
74. Djamali A, Cristol JP, Turc-Baron C, et al. Lipoprotein glomerulo-pathy: a new French case with recurrence on the transplant. Presse Med 1996;25:798-802.
75. Xin Z, Zhihong L, Shijun L, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant 2009;24:864-9.
76. Koitabashi Y, Ikoma M, Miyahira T, et al. Long-term follow-up of a paediatric case of lipoprotein glomerulopathy. Pediatr Nephrol 1990;4:122-8.
77. Bruschi M, Catarsi P, Candiano G, et al. Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulo-sclerosis. Kidney Int 2003;63:686-95.
78. van Goor H, van der Horst ML, Atmosoerodjo J, et al. Renal apolipoproteins in nephrotic rats. Am J Pathol 1993;142:1804-12.
79. Calandra S, Gherardi E, Fainaru M, et al. Secretion of lipoproteins, apolipoprotein A-I and apolipoprotein E by isolated and perfused liver of rat with experimental nephrotic syndrome. Biochim Biophys Acta 1981;665:331-8.
80. Joles JA, van Tol A, Jansen EH, et al. Plasma lipoproteins and renal apolipoproteins in rats with chronic adriamycin nephrosis. Nephrol Dial Transplant 1993;8:831-8.
81. Sun Jr X, Jones H, Joles JA, et al. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol 1992;262:755-61.
82. Kon V, Linton MF, Fazio S. Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol 2011;7:45-54.
83. Bruneval P, Bariety J, Belair MF, et al. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 2002;17:2099-107.
84. Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002;82:999-1006.
85. Bonomini F, Rodella LF, Moghadasian M, et al. Role of apolipoprotein E in renal damage protection. Histochem Cell Biol 2011;135:571-9.
86. Zhang Y, Yasumoto Y, Ikeda T, et al. Apolipoprotein E regulates primary cultured human mesangial cell proliferation. Nephron Exp Nephrol 2006;102:62-70.
87. Dai C, Stolz DB, Kiss LP, et al. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009;20:1997-2008.
88. Welsh GI, Saleem MA. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 2012;8:14-21.